CMS cuts Medicare pay for 340B drugs to ASP minus 28% in 2027 outpatient rule
Hospitals and surgery centers get a 2.3% Medicare update for 2027, but CMS will pay for 340B-acquired drugs at ASP minus 28%, cutting first-year drug payments by about $5.45 billion and shifting that sum to non-drug services.

Hospitals that buy drugs through the 340B discount program will get far less from Medicare for those drugs next year, and the money will be spread back across other outpatient services.
The Centers for Medicare & Medicaid Services on Nov. 4 finalized its 2027 rule for hospital outpatient departments and ambulatory surgical centers, setting payment for 340B-acquired drugs at the average sales price minus 28%, according to the agency's fact sheet. Hospitals and ASCs that meet quality reporting requirements get a 2.3% payment update, a projected 3.2% market basket increase less a 0.9 percentage point productivity adjustment. CMS said the rule affects about 3,500 hospitals and about 6,400 ASCs.
Why it matters: CMS estimated the 340B change will cut Original Medicare drug payments by $4.35 billion and beneficiary payments by $1.1 billion in 2027, about $5.45 billion in all. Because the law requires the policy to be budget neutral, the fact sheet said, outpatient payments for non-drug services rise by the same amount, so the cut lands on 340B drug purchases while the offset is paid out through other services.
How CMS set the rate
The new rate rests on a survey of drug acquisition costs that CMS ran from Jan. 1 through April 7, 2026, among hospitals paid under the outpatient system. The agency said the survey showed large gaps between what hospitals paid for drugs bought through 340B and drugs bought outside it. In some cases, CMS said, the patient's cost-sharing, typically 20% of the payment, was more than the hospital's entire cost for the drug.
CMS projected average drug-cost savings of $900 in 2027 for each beneficiary who gets a qualifying drug in a hospital outpatient department.
A second 340B provision speeds up a repayment set by CMS's November 2023 remedy rule. That rule recovers an estimated $7.8 billion in extra non-drug payments hospitals received from 2018 through 2022 under the agency's earlier 340B policy, by trimming the outpatient conversion factor for non-drug items and services. The trim rises from 0.5% to 2% in 2027 and stays until the $7.8 billion is recouped, which CMS now expects in 2031. Hospitals whose Medicare enrollment began after Jan. 1, 2018, are exempt.
Beyond 340B
CMS extended to imaging without contrast, such as some X-rays, bone density scans, ultrasounds, CT scans and MRIs, its practice of paying off-campus hospital outpatient departments a lower rate equivalent to the physician fee schedule. The policy already covered clinic visits and drug administration at those sites. CMS estimated savings of $260 million in 2027 and more than $9 billion from 2027 through 2036, and said rural sole community hospitals are exempt.
The rule removes 637 services from the inpatient-only list in the second year of a three-year phase-out, so Medicare can pay for them in hospital outpatient settings when clinically appropriate. CMS is also adding several hundred surgical procedures to the list it covers in ASCs, widening the range of procedures for which Medicare will pay surgery centers.
CMS will require prior authorization in hospital outpatient departments for eight more botulinum toxin injection codes. The agency said outpatient claims for those codes rose 42.8% from 2017 to 2024 while overall outpatient volume fell 8.3%, and that it could find no clinical or coding reason for the rise.
Other provisions let hospital accrediting organizations with deeming authority check compliance with certain EMTALA administrative requirements during routine surveys, and apply a cost-of-living adjustment to outpatient payments in Alaska and Hawaii that CMS projected will raise payments there by $66 million in 2027.
The rule was published in the Federal Register on Nov. 6 as a final rule with comment period and takes effect Jan. 1. The same day, CMS finalized its 2027 physician fee schedule, which separately requires 340B covered entities to report claim-level data on certain Part D drugs, with a first deadline of Sept. 30, 2027.



